PALISADE BIO, INC.
PALINasdaq
$1.97
↑ +4.2%Jul 17 close · end-of-day
Price
1Y↑ +162.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$413.0M
Enterprise Value
$280.4M
P/E
16.4
P/S
—
P/B
3.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$24.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-19.0%
ROIC
—
Debt / Equity
—
Net Cash
$132.6M
Return 1Y
+164.1%
Company profile
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company was founded in 2005 and is based in Carlsbad, California.
- CEO
- J. D. Finley
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- palisadebio.com
Management & directors
- Finley John DavidCEO, CFO
- Jones Mitchell LawrenceChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
PALI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.05↓ -89.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $13,520.00 | — | $0.00 | $250,000.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.3M | -$41.9M | -$15.7M | -$13.1M | -$14.9M | -$18.1M |
| Net income | -$10.3M | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M |
| Diluted EPS | -$3.72 | -$169.74 | -$16.53 | -$27.01 | -$10.19 | -$0.30 |
| Operating cash flow | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | -$10.8M |
| Free cash flow | -$4.8M | -$14.8M | -$13.4M | -$11.1M | -$12.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -68764.8% | — | — | -5228.0% | — | — |
| Net margin | -76346.2% | — | — | -4920.0% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$4.2M | -$3.6M | -$3.4M | -$2.3M | -$2.8M | -$2.9M | -$10.0M | -$10.7M |
| Net income | -$4.1M | -$3.5M | -$3.3M | -$2.2M | -$2.8M | -$2.9M | -$8.9M | -$9.6M |
| Diluted EPS | -$3.32 | -$2.32 | $0.04 | -$0.47 | -$0.58 | -$0.38 | $1.13 | -$0.05 |
| Operating cash flow | -$3.5M | -$3.1M | -$2.4M | -$2.3M | -$1.8M | -$3.6M | -$3.1M | -$3.9M |
| Free cash flow | — | -$3.1M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Baltera Robert Jr. | Buy | 25,000 | $1.96 | $48,900.00 | filing |
| 2026-07-08 | Baltera Robert Jr. | Buy | 20,000 | $1.99 | $39,798.00 | filing |
| 2026-07-07 | Finley John David· CEO, CFO | Sale | 146,798 | $2.07 | $303,343.39 | filing |
| 2026-07-07 | Jones Mitchell Lawrence· Chief Medical Officer | Sale | 51,880 | $2.05 | $106,535.58 | filing |
| 2026-07-07 | Baltera Robert Jr. | Buy | 30,000 | $2.03 | $61,044.00 | filing |
| 2026-07-07 | Finley John David· CEO, CFO | Option exercise | 133 | $0.70 | $93.10 | filing |
| 2026-07-06 | Baltera Robert Jr. | Buy | 20,000 | $2.05 | $41,040.00 | filing |
| 2026-07-06 | Jones Mitchell Lawrence· Chief Medical Officer | Option exercise | 131,167 | — | — | filing |
| 2026-07-06 | Finley John David· CEO, CFO | Option exercise | 335,167 | — | — | filing |
| 2026-07-02 | Baltera Robert Jr. | Buy | 10,000 | $1.98 | $19,800.00 | filing |
| 2026-07-01 | Baltera Robert Jr. | Buy | 20,000 | $1.98 | $39,600.00 | filing |
| 2026-06-10 | Wei Binxian | Award | 592,300 | — | — | filing |
| 2026-06-10 | Baltera Robert Jr. | Award | 336,904 | — | — | filing |
| 2026-06-10 | Wei Binxian | Option exercise | 20,200 | — | — | filing |
| 2026-06-10 | Williams Donald Allen | Award | 1,498,900 | — | — | filing |
| 2026-06-10 | Williams Donald Allen | Option exercise | 60,666 | — | — | filing |
| 2026-06-10 | Chuang Emil | Award | 592,300 | — | — | filing |
| 2026-06-10 | Chuang Emil | Option exercise | 20,200 | — | — | filing |
| 2026-06-10 | Zwick Jordan Michael | Award | 336,904 | — | — | filing |
| 2026-02-12 | Finley John David· CEO, CFO | Sale | 3,896 | $1.75 | $6,818.00 | filing |
| 2026-02-12 | Jones Mitchell Lawrence· Chief Medical Officer | Sale | 1,989 | $1.75 | $3,480.75 | filing |
| 2026-02-11 | Jones Mitchell Lawrence· Chief Medical Officer | Option exercise | 8,000 | — | — | filing |
| 2026-02-11 | Finley John David· CEO, CFO | Option exercise | 13,333 | — | — | filing |
| 2026-01-16 | Williams Donald Allen | Buy | 5,000 | $1.67 | $8,356.00 | filing |
| 2026-01-09 | Williams Donald Allen | Buy | 5,000 | $1.88 | $9,400.00 | filing |
Latest 25 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.